Clinical Trial Update: Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of osimertinib and aspirin in patients with EGFR-mutant non-small cell lung cancer (stage IV) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Aspirin (Aspirin)
• TAGRISSO (osimertinib)

Snippet

Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Conditions: Lung Cancer Non-small Cell Stage IV | Phase 2 | Status: COMPLETED